Asian Spine Journal

  • 제12권6호
  • /
  • Pages.1010-1016
  • /
  • 2018
  • /
  • 1976-1902(pISSN)
  • /
  • 1976-7846(eISSN)
대한척추외과학회 (Korean Society of Spine Surgery)
권호 표지
DOI QR코드

DOI QR Code

A Computed Tomography Analysis of the Success of Spinal Fusion Using Ultra-Low Dose (0.7 mg per Facet) of Recombinant Human Bone Morphogenetic Protein 2 in Multilevel Adult Degenerative Spinal Deformity Surgery

  • Liu, Gabriel (University Spine Centre, Department of Orthopaedic Surgery, National University Hospital, National University Health System) ;
  • Tan, Jun Hao (University Spine Centre, Department of Orthopaedic Surgery, National University Hospital, National University Health System) ;
  • Yang, Changwei (University Spine Centre, Department of Orthopaedic Surgery, National University Hospital, National University Health System) ;
  • Ruiz, John (University Spine Centre, Department of Orthopaedic Surgery, National University Hospital, National University Health System) ;
  • Wong, Hee-Kit (University Spine Centre, Department of Orthopaedic Surgery, National University Hospital, National University Health System)
  • 투고 : 2017.10.26
  • 심사 : 2018.05.22
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Study Design: Retrospective cohort study. Purpose: To report on spinal fusion assessment using computed tomography (CT) after adult spinal deformity (ASD) surgery using ultra-low dose recombinant human bone morphogenetic protein 2 (RhBMP-2). Overview of Literature: The reported dose of RhBMP-2 needed for successful spinal posterolateral fusion in ASD ranges from 10 to 20 mg per spinal level. This study reports the use of ultra-low dose of RhBMP-2 (0.07 mg per facet) to achieve spinal fusion in multilevel ASD surgery. Methods: Consecutive patients who underwent ASD surgery using ultra-low dose RhBMP-2 were recruited. Routine postoperative CT analysis for spinal fusion was performed by two spine surgeons. Inter-observer agreement was calculated for facet fusion (FF) and interbody fusion (IBF) at 6 and 12 months after the procedure. Results: Six consecutive ASD patients with a mean age of 62 years (28-72 years) were examined. Each patient received a total dose of 12 mg with an average dose of $0.69{\pm}0.2mg$ (0.42-1 mg) per single FF and $1.38{\pm}0.44mg$ (0.85-2 mg) for IBF. Total 131 FF and 15 IBF were examined in the study, with 88 FFs and nine IBFs being analyzed specifically at 6 months after the surgery. FF and IBF reported by surgeons A and B at 6 months were 97.7% vs. 91.9% FF, respectively (${\kappa}=0.95$) and 100% vs. 100% IBF, respectively (${\kappa}=1$). Two patients underwent longitudinal follow-up CT at 12 months, and the FF rates reported by surgeons A and B were 100% vs. 95.8%, respectively (${\kappa}=0.96$). Five out of nine facet (56%) non-unions were identified at the cross-links. The remaining four facet pseudarthrosis were noted at 1-2 spinal levels caudal to the cross-links. At the final clinical follow-up, there was no rod breakage, deformity progression, neurological deficit, or symptom recurrence. The Oswestry Disability Index improved by an average of $32.8{\pm}6.3$, while the mental component summary of the 36-item Short-Form Health Survey improved by an average of $4.7{\pm}2.1$, and physical component summary improved by an average of $10.5{\pm}2.1$. Conclusions: To our knowledge, this is the first study to report a CT that defined 92%-98% FF and 100% IBF using the lowest reported dose of RhBMP-2 in multilevel ASD surgery. The use of ultra-low dose RhBMP-2 reduces the RhBMP-2 related complications and healthcare costs.

키워드

참고문헌

  1. De Vries AA, Mullender MG, Pluymakers WJ, Castelein RM, van Royen BJ. Spinal decompensation in degenerative lumbar scoliosis. Eur Spine J 2010;19:1540-4. https://doi.org/10.1007/s00586-010-1368-z
  2. Oskouian RJ Jr, Shaffrey CI. Degenerative lumbar scoliosis. Neurosurg Clin N Am 2006;17:299-315. https://doi.org/10.1016/j.nec.2006.05.002
  3. Ploumis A, Transfledt EE, Denis F. Degenerative lumbar scoliosis associated with spinal stenosis. Spine J 2007;7:428-36. https://doi.org/10.1016/j.spinee.2006.07.015
  4. Schwab F, el-Fegoun AB, Gamez L, Goodman H, Farcy JP. A lumbar classification of scoliosis in the adult patient: preliminary approach. Spine (Phila Pa 1976) 2005;30:1670-3. https://doi.org/10.1097/01.brs.0000170293.81234.f0
  5. Liu G, Tan JH, Ee G, Chan YH, Low SL, Wong HK. Morphology and prevalence study of lumbar scoliosis in 7,075 multiracial Asian adults. J Bone Joint Surg Am 2016;98:1307-12. https://doi.org/10.2106/JBJS.15.00710
  6. Deyo RA, Cherkin DC, Loeser JD, Bigos SJ, Ciol MA. Morbidity and mortality in association with operations on the lumbar spine: the influence of age, diagnosis, and procedure. J Bone Joint Surg Am 1992;74:536-43. https://doi.org/10.2106/00004623-199274040-00009
  7. Yadla S, Maltenfort MG, Ratliff JK, Harrop JS. Adult scoliosis surgery outcomes: a systematic review. Neurosurg Focus 2010;28:E3.
  8. Swank S, Lonstein JE, Moe JH, Winter RB, Bradford DS. Surgical treatment of adult scoliosis: a review of two hundred and twenty-two cases. J Bone Joint Surg Am 1981;63:268-87. https://doi.org/10.2106/00004623-198163020-00013
  9. Buttermann GR, Glazer PA, Hu SS, Bradford DS. Anterior and posterior allografts in symptomatic thoracolumbar deformity. J Spinal Disord 2001;14:54-66. https://doi.org/10.1097/00002517-200102000-00009
  10. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-9. https://doi.org/10.1126/science.150.3698.893
  11. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-34. https://doi.org/10.1126/science.3201241
  12. Singh K, Smucker JD, Gill S, Boden SD. Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolateral lumbar spine fusion: a prospective CT-scan analysis at one and two years. J Spinal Disord Tech 2006;19:416-23. https://doi.org/10.1097/00024720-200608000-00008
  13. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002;27:2662-73. https://doi.org/10.1097/00007632-200212010-00005
  14. Dimar JR 2nd, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 2009;91:1377-86. https://doi.org/10.2106/JBJS.H.00200
  15. Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976) 2006;31:2534-9. https://doi.org/10.1097/01.brs.0000240715.78657.81
  16. Chrastil J, Low JB, Whang PG, Patel AA. Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine. Spine (Phila Pa 1976) 2013;38:E1020-7. https://doi.org/10.1097/BRS.0b013e3182982f8e
  17. Devine JG, Dettori JR, France JC, Brodt E, McGuire RA. The use of rhBMP in spine surgery: is there a cancer risk? Evid Based Spine Care J 2012;3:35-41.
  18. Glassman SD, Howard J, Dimar J, Sweet A, Wilson G, Carreon L. Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases. Spine (Phila Pa 1976) 2011;36:1849-54. https://doi.org/10.1097/BRS.0b013e3181d133d0
  19. Food and Drug Administration. Summary of safety and effectiveness data (SSED) [Internet]. Silver Spring (MD): Food and Drug Administration; 2010 [cited 2016 Jun 30]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100027b.pdf.
  20. Villavicencio AT, Burneikiene S. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose. Spine J 2016;16:1208-13. https://doi.org/10.1016/j.spinee.2016.06.007
  21. Mannion RJ, Nowitzke AM, Wood MJ. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2: but what is the cost? Spine J 2011;11:527-33. https://doi.org/10.1016/j.spinee.2010.07.005
  22. Crandall DG, Revella J, Patterson J, Huish E, Chang M, McLemore R. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease: part 2. BMP dosage- related complications and long-term outcomes in 509 patients. Spine (Phila Pa 1976) 2013;38:1137-45. https://doi.org/10.1097/BRS.0b013e3182880298
  23. Copay AG, Glassman SD, Subach BR, Berven S, Schuler TC, Carreon LY. Minimum clinically important difference in lumbar spine surgery patients: a choice of methods using the Oswestry Disability Index, Medical Outcomes Study questionnaire Short Form 36, and pain scales. Spine J 2008;8:968-74. https://doi.org/10.1016/j.spinee.2007.11.006
  24. Kim YJ, Bridwell KH, Lenke LG, Cho KJ, Edwards CC 2nd, Rinella AS. Pseudarthrosis in adult spinal deformity following multisegmental instrumentation and arthrodesis. J Bone Joint Surg Am 2006;88:721-8.
  25. Kim YJ, Bridwell KH, Lenke LG, Rinella AS, Edwards C 2nd. Pseudarthrosis in primary fusions for adult idiopathic scoliosis: incidence, risk factors, and outcome analysis. Spine (Phila Pa 1976) 2005;30:468-74. https://doi.org/10.1097/01.brs.0000153392.74639.ea
  26. Kim HJ, Buchowski JM, Zebala LP, Dickson DD, Koester L, Bridwell KH. RhBMP-2 is superior to iliac crest bone graft for long fusions to the sacrum in adult spinal deformity: 4- to 14-year follow-up. Spine (Phila Pa 1976) 2013;38:1209-15. https://doi.org/10.1097/BRS.0b013e31828b656d
  27. Crandall DG, Revella J, Patterson J, Huish E, Chang M, McLemore R. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease: part 1. large series diagnosis related outcomes and complications with 2- to 9-year follow-up. Spine (Phila Pa 1976) 2013;38:1128-36. https://doi.org/10.1097/BRS.0b013e31828864e6
  28. Maeda T, Buchowski JM, Kim YJ, Mishiro T, Bridwell KH. Long adult spinal deformity fusion to the sacrum using rhBMP-2 versus autogenous iliac crest bone graft. Spine (Phila Pa 1976) 2009;34:2205-12. https://doi.org/10.1097/BRS.0b013e3181b0485c
  29. Mulconrey DS, Bridwell KH, Flynn J, Cronen GA, Rose PS. Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum twoyear evaluation of fusion. Spine (Phila Pa 1976) 2008;33:2153-9. https://doi.org/10.1097/BRS.0b013e31817bd91e
  30. Buchowski JM, Liu G, Bunmaprasert T, Rose PS, Riew KD. Anterior cervical fusion assessment: surgical exploration versus radiographic evaluation. Spine (Phila Pa 1976) 2008;33:1185-91. https://doi.org/10.1097/BRS.0b013e318171927c

피인용 문헌

  1. Failure Types and Related Factors of Spinopelvic Fixation After Long Construct Fusion for Adult Spinal Deformity vol.88, pp.3, 2021, https://doi.org/10.1093/neuros/nyaa469
  2. Metal failure and nonunion at L5-S1 after long instrumented fusion distal to pelvis for adult spinal deformity: Anterior versus transforaminal interbody fusion vol.29, pp.3, 2018, https://doi.org/10.1177/23094990211054223
  3. Comparison of demineralized bone matrix and hydroxyapatite as carriers of Escherichia coli recombinant human BMP-2 vol.25, pp.1, 2021, https://doi.org/10.1186/s40824-021-00225-7